Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Child, 2 months to 10 years of age~* Body weight less than 42 kg~* Presenting at emergency department with mild to moderate dehydration (Gorelick dehydration classification: presence of 1 to 6 \[of possible 10\] moderate or severe signs and symptoms) requiring parenteral rehydration~Exclusion Criteria:~* In shock or life-threatening situation (other than dehydration)~* Severe dehydration~* Requires intravenous (IV) therapy for another indication~* Indwelling IV catheter (excepting one intended strictly for clinical laboratory sample collection)~* Already received rehydration therapy IV within prior 48 hours or substantial oral fluid immediately before enrollment~* Condition precluding subcutaneous injection or infusion site evaluation in anterior thigh or other elected infusion site~* Reason for hospital admission or extended emergency department stay other than dehydration~* Known hypersensitivity to hyaluronidase or another ingredient in HYLENEX~* Hyponatremia or hypernatremia~* Hypokalemia~* Medical condition likely to interfere with ability to fully complete study or have protocol-specified assessments~* Medical history, screening examination finding or historical clinical laboratory result precluding safe participation in study or which might adversely effect interpretation of study results~* Participated in study of any investigational drug or device within 30 days prior to this study

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- HYLENEX-augmented subcutaneous (SC ) rehydration (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).